Clinical Trials
12 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT05650476 2025-06-12
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Pfizer
Available
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT04337099 2021-05-05
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
Matrix Biomed, Inc.
Available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT01834209 2018-11-07
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
No longer available
NCT01217697 2017-03-24
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Approved for marketing
NCT01516762 2014-07-14
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
No longer available
NCT00636259 2008-06-11
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
AstraZeneca
No longer available